The phase 3 #IMPower151 trial evaluated atezolizumab + bevacizumab + CT (ABCPem/Pac) vs bevacizumab + CT (BCPem/Pac) in 305 Chinese pts with metastatic nsqNSCLC

#NatureMedicine @natureportfolio.nature.com

#Onco404 #Cancer #Kanser #LungCancer #Immunotherapy #ClinicalTrials #PrimaryEndpoint #MedSky

🌍 Regional Context
❌ Unlike global #IMPower150 (which showed significant PFS/OS benefits), #IMPower151 highlights differences in Asian vs. Western populations: 53% had #EGFR mutations (vs. 14% in IMP150) and 97% used pemetrexed (vs. paclitaxel in IMP150).

#Onco404 #Cancer #Kanser #MedSky #OncSky